reference/20969751

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/20969751

Outgoing Links

Predicate	Object
contentType	Journal Article\|Research Support, N.I.H., Extramural\|Research Support, Non-U.S. Gov't
endingPage	2630
issn	1525-0016
issueIdentifier	11
pageRange	2617-2630
publicationName	Molecular therapy : the journal of the American Society of Gene Therapy
startingPage	2617
hasFundingAgency	http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_c9715a34c9ccde7ccc72cadee3277b94 http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_93b55ea59c439e8071d2c6c488868a64 http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_8575d755e30073009e847d1c086e8fbe
isSupportedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_327232f1f3b9c9c2125fa93948f38ca0
bibliographicCitation	Wang Y, Hao L, Wang H, Santostefano K, Thapa A, Cleary J, Li H, Guo X, Terada N, Ashizawa T, Xia G. Therapeutic Genome Editing for Myotonic Dystrophy Type 1 Using CRISPR/Cas9. Molecular Therapy. 2018 Nov;26(11):2617–30. doi: 10.1016/j.ymthe.2018.09.003.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_1c7aa677dda554ba99780dd4abbcd403 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5bba0d908482f7871cf27fd4a37e9502 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a47932ddac36c994c31d2c387c13258c http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_347daba9b5ebcfc4dca433979b47a801 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_77a2162361600bd4d20df5521758a7d9 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_336d832c9b1d40dc3748d39c51770fc4 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_fe9ecab82da631574b1e31de06f33b9f http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_6787e8c64e19b3d9a675215d2c4e8ae7 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_55f117cb378802eee1434154f7e33229 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_91298a6116eb87c3ef19383d9db85581 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_0b2b030e974051887c1bdcfbd82d54ed
date	2018-11-07-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://pubmed.ncbi.nlm.nih.gov/30274788 https://doi.org/10.1016/j.ymthe.2018.09.003 https://pubmed.ncbi.nlm.nih.gov/PMC6225032
isPartOf	http://rdf.ncbi.nlm.nih.gov/pubchem/journal/21793 https://portal.issn.org/resource/ISSN/1525-0016
language	English
source	https://pubmed.ncbi.nlm.nih.gov/ https://www.crossref.org/
title	Therapeutic Genome Editing for Myotonic Dystrophy Type 1 Using CRISPR/Cas9
discusses	http://id.nlm.nih.gov/mesh/M0590267 http://id.nlm.nih.gov/mesh/M0030068 http://id.nlm.nih.gov/mesh/M000756254 http://id.nlm.nih.gov/mesh/M0472556
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D065636Q000235 http://id.nlm.nih.gov/mesh/D009223Q000235 http://id.nlm.nih.gov/mesh/D058953Q000502 http://id.nlm.nih.gov/mesh/D019680Q000235
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D057809 http://id.nlm.nih.gov/mesh/D018482Q000254 http://id.nlm.nih.gov/mesh/D020413 http://id.nlm.nih.gov/mesh/D064113Q000235 http://id.nlm.nih.gov/mesh/D009474Q000502 http://id.nlm.nih.gov/mesh/D039104Q000235 http://id.nlm.nih.gov/mesh/D014162 http://id.nlm.nih.gov/mesh/D000094704 http://id.nlm.nih.gov/mesh/D009223Q000628 http://id.nlm.nih.gov/mesh/D009223Q000473 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D000072669Q000379 http://id.nlm.nih.gov/mesh/D015316Q000379 http://id.nlm.nih.gov/mesh/D032383Q000502 http://id.nlm.nih.gov/mesh/D002454Q000235
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8576 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_b60e7841ce141c73cb0fd4d93079c52d http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_d19b02b7fcdfca9270b43e97532671e4

Incoming Links

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID1760

Total number of triples: 60.